The Silicon Review - Best Business Review Magazine Super 30 Companies of the Year 2019 | Page 33

•
•
segment (15% in labs and 10%
in radiology)
The primary care industry is
currently valued at $ 13 bn. The
share of organized sector is
practically negligible in this case
100% FDI is allowed under the
automatic route for greenfield
projects. For investments in
brownfield projects, up to 100%
FDI is permitted under the
government route
In light of the foregoing, we present
Alniche Life Sciences Pvt Ltd – a
specialty healthcare firm.
Alniche serves patients and the
medical fraternity by offering
specialized, high-quality, effective
and affordable drugs and wellness
products from all around the world.
A strong portfolio with products
licensed from global partners fulfils
the unmet needs of patients in the
areas of nephrology, critical care,
gastroenterology, dermatology, and
advanced wound care.
The firm was incorporated in 2007
and is headquartered in New Delhi,
India. Alniche’s efforts have been
recognised and received following
awards
• Business man of the year – by
Business Sphere
• Healthcare Elite – by Business
APAC
• Fastest growing brands &
leadership – by Asia one
“
Girish Arora, Alniche
Life Sciences Pvt. Ltd
Founder/Managing
Director, spoke
exclusively to
The Silicon Review.
Below is an excerpt.
What makes Alniche stand
out from the competition?
Being very strong in niche therapies,
Alniche has a focus on Nephrology,
Critical care, Gastroenterology,
Skinceuticals and Advanced wound
care products. It is dedicated
to making available innovative
pharmaceutical products in the
Indian market and support medical
fraternity in making patients’ lives
healthier. The firm is ready to mark
its existence in the complementary
market of medical devices and
consumables in the selected
therapy areas that align well with
their pharma range and one such
initiative of the firm is an entry in
the advanced wound care segment.
Alniche provides specialized, high
quality, effective, and affordable
medicine and wellness products.
Alniche continuously looks for
opportunities to partner with global
pharma companies and promotes
deep engagement with medical
experts. Strategic focus and a
differentiated approach empower
the company to strengthen new
speciality divisions by addressing
the therapy gaps. In-licensing of
novel products in future growth
areas is a critical piece of the overall
strategy of the company.
The consolidation of strategic focus
with a differentiated approach
empowers the firm to follow the
new speciality divisions where
therapy gaps are significant. There
are various factors focused by
the firm regarding in-licencing
addressing future growth areas,
acquiring an existing base to
build upon including technology,
manufacturing, marketing, etc.
Cost and time advantages are also
considered along with enhanced
expertise and global accessibility.
Alniche has partnered with global
pharma organizations to bring
novel global brands in India from
various organizations including
J.W. Life Sciences (Korea), Adhezion
Biomedical Inc. (USA), FzioMed
(USA), Advancis Medical (UK), PT
Dermozone Pratama (Indonesia),
Biovite (Australia), and Mastix
(USA). In addition, the firm is also
collaborating with various global
companies that focus on therapy
differentiation and ground-breaking
product concepts.
Recently, Alniche has formed
an R&D alliance with Delhi
Pharmaceutical Sciences & Research
University (DPSRU) – India’s first
Pharmacy University. This affiliation
of industry and academia promises
to augment further development of
We travelled from a sales-and-marketing structure to a business
unit one to ensure more accountability, manage evolving
business needs, and use the equity of organization for reaching
out to a different set of prescribers.”
AUGUST 2019
33